Pattern of Immunophenotypic Aberrant Expression in De-Novo Acute Leukaemia

Abstract

Background: Aberrant expression (AE) of Acute Leukaemia (AL) is essential to confirm the diagnosis of AL patients whether it is biphenotypic/mix phenotypic AL or it is AL with AE. Objectives: This study is conducted to observe the diversity of aberrant immunophenotypic expressions among the patients of acute leukaemia with varying frequencies, to find out the correlation between aberrantly expressed immunophenotypic markers with different variety of French American British (FAB) sub classification of acute leukaemia and any correlation of clinical presentation of AL patients with aberrantly expressed immunophenotypic markers. Methodology: This cross-sectional observational study was carried out in the department of Haematology, BSMMU, Bangladesh on 50 patients from 14 to 65 years of age of both sex of newly diagnosed de- novo untreated AL patients from January 2017 to June 2018. Informed written consent & clinical history is taken and physical examinations were done in a predesigned data collection sheet. Then Bone marrow (BM) with peripheral blood sample for morphology and immunophenotyping were done in the laboratory of the Haematology department of BSMMU. After collection of data, these data were analysed for the final result. Result: In this study, 24 (48%) patients of de-novo Acute Leukaemia have Immunophenotypic aberrant expressions. Among them 12 (24%) patients were AML with AE, 9 (18%) patients were B ALL with AE, 3 (6%) patients were T ALL with AE and 2 (4%) patients were MPAL. In case of AML the most frequent Lymphoid aberrant marker is CD7 (12%), In B ALL the most frequent aberrant marker is CD5 (10%) and in T ALL the most frequent aberrant marker is CD10 (4%). Conclusion: In de-novo acute leukaemia, there is significant number of patients have aberrant expression which should be differentiated from biphenotypic/mix phenotypic AL for therapeutic and prognostic implications.